Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Merck Sharp & Dohme LLC368 enrolled

Overview

This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered in combination with peginterferon alfa-2b (Peg-IFN) and ribavirin (RBV) in treatment-naïve (TN) participants with chronic hepatitis C.

Amendment 4 unblinded treatment after an interim analysis for all subsequently enrolled TN participants (the Second Cohort) who were receiving grazoprevir 400 or 800 mg daily, and they were down-dosed to 100 mg daily between Treatment Week (TW) 3 and TW12 for the remainder of the 12-week treatment course. Amendment 5 allowed treatment-naïve participants with chronic hepatitis C and compensated cirrhosis to be enrolled and receive open-label grazoprevir 100 mg in combination with Peg-IFN and RBV, without a corresponding control arm.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

368

Conditions

Hepatitis C, Chronic

Interventions

GrazoprevirDRUG

Orally once daily in AM. Blinded or open-label depending on treatment arm.

BoceprevirDRUG

Four 200 mg capsules orally three times daily.

Placebo for GrazoprevirDRUG

Orally once daily in AM.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has previously documented chronic hepatitis C genotype 1 (CHC GT 1) infection * Has hepatitis C virus (HCV) ribonucleic acid (RNA value) ≥10,000 IU/mL * Body weight ≥40 kg (88 lbs) and ≤125 kg (275 lbs) * Absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs and symptoms of decompensated liver disease * Had a liver biopsy within 3 years of screening or between screening and Day 1 with histology consistent with CHC and no evidence of cirrhosis or hepatocellular carcinoma or no other cause for chronic liver disease (for participants with compensated cirrhosis, any liver biopsy demonstrating cirrhosis regardless of length of time since biopsy) * Female of childbearing potential or a male with female sexual partner who is of childbearing potential agrees to use two acceptable methods of birth control from at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations * For participants with compensated cirrhosis, evidence of cirrhosis without evidence of hepatocellular carcinoma (confirmed by ultrasound within 4 weeks prior) Exclusion Criteria: * Is pregnant, breastfeeding, or plans to become pregnant or donate eggs * Is human immunodeficiency virus (HIV) positive or known to be co-infected with hepatitis B virus * Has received prior approved or investigational treatment for hepatitis C * Has evidence of hepatocellular carcinoma or is under evaluation for hepatocellular carcinoma * For participants with compensated cirrhosis: alphafetoprotein level of ≥100 ng/mL * Has evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years * Has evidence or history of chronic hepatitis not caused by HCV * Is diabetic and/or hypertensive with clinically significant ocular examination findings: retinopathy, cotton wool spots, optic nerve disorder, retinal hemorrhage, or any other clinically significant abnormality * Has any known medical condition that could interfere with participation in and completion of the study * Pre-existing psychiatric condition including but not limited to moderate or severe depression, suicidal or homicidal ideation or attempt, schizophrenia, psychosis, bipolar disorder, post traumatic stress disorder, or mania * Is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent * Member or family member of study staff

Outcomes

Primary Outcomes

Percentage of Participants Achieving Complete Early Viral Response (cEVR)

Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). cEVR was defined as undetectable HCV RNA (target not detected \[TND\]) at Week 12. 95% confidence intervals provided based on the Clopper-Pearson method.

Time frame: After 12 weeks of treatment with grazoprevir/boceprevir

Number of Participants Experiencing Adverse Events (AEs) During the Treatment Period and First 14 Follow-up Days

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, was also an AE.

Time frame: Treatment period plus the first 14 days of follow-up (up to 50 weeks)

Number of Participants Who Discontinued Study Medication Due to AEs During the Treatment Period and First 14 Follow-up Days

Time frame: Treatment period plus the first 14 days of follow-up (up to 50 weeks)

Secondary Outcomes

Median Time to First Achievement of Undetectable HCV RNA During Treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.